NCT01567163View on ClinicalTrials.gov

A Study of Ramucirumab and Docetaxel in Participants With Solid Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

December 31, 2012

Study Completion Date

March 31, 2014

Conditions
Malignant Solid Tumor
Interventions
BIOLOGICAL

Ramucirumab

ramucirumab 10 milligrams/kilogram (mg/kg) intravenous infusion, administered on Day 1 of 3-week cycle

DRUG

Docetaxel

docetaxel 75 milligrams/square meter (mg/m\^2) intravenous infusion administered on Day 1 of each 3-week cycle

Trial Locations (6)

28078

ImClone Investigational Site, Huntersville

44195

ImClone Investigational Site, Cleveland

48109

ImClone Investigational Site, Ann Arbor

48202

ImClone Investigational Site, Detroit

98109

ImClone Investigational Site, Seattle

08901

ImClone Investigational Site, New Brunswick

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT01567163 - A Study of Ramucirumab and Docetaxel in Participants With Solid Tumors | Biotech Hunter | Biotech Hunter